RxDoctor Payments Data

Derek Carlson

Child & Adolescent Psychiatry · Green Bay, WINPI 1790775450

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $38,608 of the $54,447 with a category attached, or 70.9%. 20 manufacturers reported payments, led by Ironshore Pharmaceuticals Inc. at 59.6% of the total. Reporting peaked in 2019 at $25,773 and has fallen 99.1% since, to $227 in 2025. Among child & adolescent psychiatry clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$54,447in general payments, 2019–2025

Across 311 payments — averaging $175.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ironshore Pharmaceuticals Inc.$32K
  • Supernus Pharmaceuticals, Inc.$13K
  • Corium, LLC$8K
  • Lundbeck LLC$154
  • Sunovion Pharmaceuticals Inc.$116
  • AbbVie$111
  • plus $540 from 14 others

What the payments were for

  • Consulting fees$5,26010%
  • Speaking & faculty fees$38,60871%
  • Travel & lodging$5,89611%
  • Food & beverage$4,6839%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$54,447 in reported general payments places this provider in the 95th percentile of 49 child & adolescent psychiatry providers in Wisconsin.

See all child & adolescent psychiatry providers in Wisconsin

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl17$24,764
VyvanseLisdexamfetamine Dimesylate33$14,231
TrintellixVortioxetine Hydrobromide11$5,369
Focalin XrDexmethylphenidate Hcl12$5,053
Lisdexamfetamine Dimesylate20$3,712
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine39$2,305
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine56$1,958
Divalproex Sodium ErDivalproex Sodium33$1,676
Guanfacine Hcl ErGuanfacine Hcl46$1,458
Olanzapine OdtOlanzapine19$1,381
Aripiprazole11$1,324
Oxcarbazepine19$1,323
Olanzapine49$1,259
Lamotrigine85$1,151
Hydroxyzine Hcl33$1,036

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$111$24,76417 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix$56$19,60044 claims
Almatica Pharma LLCSertraline Hcl$14$18621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 49 child & adolescent psychiatry providers in Wisconsin.

Other child & adolescent psychiatry in Green Bay

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →